CAS
HQL

CTC Alternative Strategies’s abrdn Life Sciences Investors HQL Stock Holding History

CTC Alternative Strategies’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,112
Closed -$150K – 162
2023
Q4 		$150K Buy
+11,112
New +$137K 0.31% 42

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
AIA
Absolute Investment Advisers Rosemary Beach, Florida $852M AUM 0.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

CTC Alternative Strategies's HQL Position: Q1 2024 in Review

CTC Alternative Strategies sold out of abrdn Life Sciences Investors (HQL) in Q1 2024, closing a stake of 11,112 shares — an estimated $150K sold.

CTC Alternative Strategies first reported a position in HQL in Q4 2023 and held it in 1 quarter. The position peaked at $150K in Q4 2023. 79 funds tracked by Wall St. Rank hold HQL as of Q1 2024.

  • CTC Alternative Strategies reported no remaining abrdn Life Sciences Investors position as of Q1 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 11,112 abrdn Life Sciences Investors shares in Q1 2024, an estimated $150K.
  • CTC Alternative Strategies first reported a position in abrdn Life Sciences Investors in Q4 2023 and held it in 1 quarter.
  • CTC Alternative Strategies's abrdn Life Sciences Investors position peaked at $150K in Q4 2023.
  • 79 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2024.

Based on CTC Alternative Strategies's 13F filing for Q1 2024, filed 9 May 2024.